Welcome to our dedicated page for Bioxcel Therapeutics SEC filings (Ticker: BTAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) files a range of documents with the U.S. Securities and Exchange Commission (SEC) that provide detail on its business, risks, governance, and financial condition. As a biopharmaceutical company using artificial intelligence to develop medicines in neuroscience, its SEC filings are a key source for understanding the status of IGALMI (dexmedetomidine) sublingual film, the BXCL501 clinical program, and broader pipeline and corporate activities.
On this page, you can review BioXcel Therapeutics’ current and historical SEC filings, including annual and quarterly reports that discuss its operating losses, funding needs, indebtedness, and going‑concern considerations, as well as risk factors related to IGALMI, BXCL501, BXCL502, BXCL701, and BXCL702. Form 8‑K filings capture material events such as positive topline data from the SERENITY At‑Home Pivotal Phase 3 trial, correlation study results, updates on the timing of a planned supplemental New Drug Application (sNDA) for IGALMI label expansion to at‑home use, financing transactions under an at‑the‑market equity program, and Nasdaq listing compliance notices.
Proxy materials, such as the company’s definitive proxy statement on Schedule 14A, provide information on director elections, advisory votes on executive compensation, auditor ratification, and proposals like a reverse stock split authorization to help maintain Nasdaq listing requirements. These documents also describe the board structure, committee responsibilities, and stockholder voting outcomes.
Stock Titan enhances access to these filings with AI‑powered summaries that explain complex sections in plain language, highlight key points from lengthy reports, and help users quickly locate disclosures on topics such as clinical program updates, capital structure changes, or governance matters. Real‑time integration with the SEC’s EDGAR system allows new filings, including 10‑K annual reports, 10‑Q quarterly reports, 8‑K current reports, and any Form 4 insider transaction filings, to appear promptly with concise AI insights. This makes it easier for investors, analysts, and other interested readers to follow how BioXcel Therapeutics’ regulatory, clinical, and financial profile evolves over time.
BioXcel Therapeutics (BTAI) filed an 8-K announcing it has submitted a pre-supplemental NDA (pre-sNDA) package to the FDA seeking to expand IGALMI’s label to cover at-home treatment of acute agitation in schizophrenia or bipolar disorders. The FDA has scheduled the pre-sNDA meeting for 20 Aug 2025; BioXcel aims to confirm alignment on data requirements and formatting before filing the full sNDA. Management also intends to reconfirm guidance from a 6 Mar 2024 Type C meeting, in which the FDA deemed the company’s development plan a reasonable path to support the proposed 120 mcg BXCL501 outpatient indication.
No financial metrics were disclosed. The filing consists primarily of regulatory updates and forward-looking statements reminding investors of associated risks. Successful FDA agreement could open a materially larger market by allowing IGALMI to be self-administered outside clinical settings, but approval is still contingent on future FDA review.